Gefjon Pharma has developed a groundbreaking platform technology based on our unique hyper vesiculating outer membrane vesicle (OMV) technology. This combined with our unique extraction method enable high-yield cost-effective production of bio-industrials and therapeutics.
Our first product is a revolutionary broad-protective bacterial E. coli vaccine targeting poultry production. We have PoC for both the vaccine and an aerosol application method.
With E. coli being the single most important cause of mortality and infections in poultry, we will significantly reduce global consumption of antimicrobials, thereby minimizing the development of antimicrobial resistance (AMR), improve animal welfare, and reduce CO2 emissions and food waste, while increasing customer profits.
With our excellent customer relations and a strong demand for new vaccines, market entry barriers are low, and the potential is massive.
Company Details
- Employees
- 7
- Founded
- -
- Address
- Ole Maaløes Vej, 3,denmark
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Copenhagen, Capital Region of Denmark
Gefjon Pharma Questions
Gefjon Pharma's LinkedIn profile is https://dk.linkedin.com/company/gefjon-pharma
Gefjon Pharma has
7 employees.
View email and phone details for 7
employees at Gefjon Pharma.
Gefjon Pharma's industry is
Biotechnology Research
Gefjon Pharma's top competitors are
Incipiam Pharma,
Midas Pharma,
Akasi Pharma,
Bioinnovation Institute,
Proxi Biotech,
Microminer,
Yngvi Bio,
Xterna,
Synuca Therapeutics,
Beech Biotech Sa.
Gefjon Pharma's categories are Biotechnology Research
Gefjon Pharma's founding year is 2023
